Org 2766 prevents disruption of vestibular compensation by an NMDA receptor antagonist.
The adrenocorticotrophic hormone fragment 4-9 (ACTH-(4-9)) analog, Org 2766 has been shown to accelerate vestibular compensation. However, N-methyl-D-aspartate (NMDA) receptor antagonists disrupt the recovery process. When Org 2766 was administered at a dose of 20 nmol/kg every 4 h for 52 h, it prevented the disruption of compensation usually produced by a single 5 mg/kg i.p. injection of the NMDA receptor antagonist 3-([+]-2-carboxy-piperazin-4yl)-propyl-1-phosphonic acid (CPP). NMDA receptor antagonists and ACTH-like peptides may produce their effects on compensation by acting directly or indirectly at the same receptor complex.
Gilchrist
D
D
Department of Psychology, University of Otago, Dunedin, New Zealand.
Darlington
C
C
Smith
P
P
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D006168:Guinea Pigs; D010446:Peptide Fragments / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D014724:Vestibular Function Tests; D014722:Vestibule, Labyrinth / Q000187:drug effects* / Q000502:physiology
D000927:Anticonvulsants; D010446:Peptide Fragments; D010879:Piperazines; D016194:Receptors, N-Methyl-D-Aspartate; C013765:Org 2766; D000324:Adrenocorticotropic Hormone; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid